Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?

Sasanka M. HandunnettiClinical Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, AustraliaCorrespondence[email protected]

http://orcid.org/0000-0001-8790-4675 View further author information

Constantine S. TamClinical Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

https://orcid.org/0000-0002-9759-5017 View further author information

Click to increase image sizeClick to decrease image size

Disclosure statement

Dr. Tam reports grants and personal fees from Janssen, grants and personal fees from Abbvie, grants and personal fees from Beigene, during the conduct of the study.

Additional information

Funding

For author S. H. Handunnetti: Honoraria from Gilead & Roche; travel expenses from AbbVie; non-financial assistance from Novartis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?

Information for

Open access

Opportunities

Help and information

Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature